Imaging of tumour hypoxia using PET and 18F-labelled tracers: Biology meets technology

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 10, 2007, Pages 1563-1565

  Grönroos, Tove ^a   Minn, Heikki ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; FLUORINE 18; FLUOROAZOMYCINARABINOSIDE F 18; FLUOROERYTHRONITROIMIDAZOLE F 18; FLUOROETANIDAZOLE F 18; NITROIMIDAZOLE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

HEAD CANCER; HUMAN; HYPOXIA; INTENSITY MODULATED RADIATION THERAPY; LUNG CANCER; NECK CANCER; NOTE; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER;

ANIMALS; BIOLOGY; CELL HYPOXIA; FLUORINE RADIOISOTOPES; HUMANS; NEOPLASMS; OXYGEN; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 34748849510     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0487-1     Document Type: Note

References (22)

1. Horsman MR, Overgaard J. The oxygen effect and tumour microenvironment. In: Steel GG, editor. Basic clinical radiobiology. London: Arnold; 2002; p. 158-68.
2. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88-91.
3. McCalla DR, Reuvers A, Kaiser C. Mode of action of nitrofurazone. J Bacteriol 1970;104:1126-34.
4. 18F-misonidazole PET-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group study 98.02. J Clin Oncol 2006;24:2098-104.
5. Thorwarth D, Eschmann SM, Paulsen F, Alber M. Hypoxia dose painting by numbers: a planning study. Int J Radiat Oncol Biol Phys 2007;68:291-300.
6. Chapman JD. Hypoxic sensitizers-implications for radiation therapy. N Engl J Med 1979;301:1429-32.
7. Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 2005;6:112-7.
8. 18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996;36:417-28.
9. Kubota K, Tada M, Yamada S, Hori K, Saito S, Iwata R, et al. Comparison of the distribution of fluorine-18 fluoromisonidazole, deoxyglucose and methionine in tumour tissue. Eur J Nucl Med 1999;26:750-7.
10. Yang DJ, Wallace S, Cherif A, Li C, Gretzer MB, Kim EE, et al. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology 1995;194:795-800.
11. 18F] fluoroerythronitroimidazole: a potential hypoxia marker for PET. J Nucl Med 2001;42:1397-404.
12. 18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia. J Nucl Med 1999;40:1072-9.
13. 18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol 2003;30:317-26.
14. 18F-fluoroazomycin arabinoside. J Nucl Med 2005;46:106-13.
15. 18F]EF3 uptake on an individual mouse tumour basis. Eur J Nucl Med Mol Imaging 2006;33:553-6.
16. 18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure. Appl Radiat Isot 2001;54:73-80.
17. 18F-EF5. Eur J Nucl Med Mol Imaging 2003;30:259-66.
18. 18F] fluoroerythronitroimidazole PET. J Nucl Med 2001;42:1643-52.
19. Lehtiö K, Eskola O, Viljanen T, Oikonen V, Grönroos T, Sillanmäki L, et al. Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004;59:971-82.
20. 18F]FMISO in an experimental mammary carcinoma. Eur J Nucl Med Mol Imaging 2004;31:513-20.
21. 18F]FAZA PET in head and neck cancer patients: a pilot study. Eur J Nucl Med Mol Imaging 2007; DOI 10.1007/s00259-007-0424-3.
22. 123I-IAZA in healthy volunteers. J Nucl Med 2001;42:1418-23.